Koers Immunoprecise Antibodies Ltd Other OTC
Aandelen
CA87588T1030
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 18 mln. 16,81 mln. | Omzet 2025 * | 29,82 mln. 21,83 mln. 20,39 mln. | Marktkapitalisatie | 35,94 mln. 26,31 mln. 24,57 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,79 mln. -8,2 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,59 mln. -6,15 mln. | EV/omzet 2024 * | 1,46 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,21 x |
K/w-verhouding 2024 * |
-2,85
x | K/w-verhouding 2025 * |
-3,86
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over Immunoprecise Antibodies Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,73% | 94,22 mld. | |
-3,42% | 37,76 mld. | |
-13,75% | 32,5 mld. | |
+73,19% | 27,75 mld. | |
-11,88% | 16,13 mld. | |
+0,49% | 14,19 mld. | |
-12,95% | 11,42 mld. | |
+190,36% | 11,06 mld. | |
-54,07% | 9,09 mld. |